Emerging bone problems in patients infected with human immunodeficiency virus

被引:65
作者
Mondy, K [1 ]
Tebas, P [1 ]
机构
[1] Washington Univ, Sch Med, Div Infect Dis, AIDS Clin Trials Unit, St Louis, MO 63110 USA
关键词
D O I
10.1086/367566
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recently, a high incidence of osteopenia and osteoporosis has been observed in individuals infected with human immunodeficiency virus (HIV). This problem appears to be more frequent in patients receiving potent antiretroviral therapy. Other bone-related complications in HIV-infected individuals, including avascular necrosis of the hip and compression fracture of the lumbar spine, have also been reported. People living with HIV have significant alterations in bone metabolism, regardless of whether they are receiving potent antiretroviral therapy. The underlying mechanisms to account for these observations remain unknown, although studies are underway to examine the relationship between the bone abnormalities and other complications associated with HIV and antiretroviral therapy. HIV-infected patients with osteopenia or osteoporosis should be treated similarly to HIV-seronegative patients with appropriate use of nutritional supplements ( calcium and vitamin D) and exercise. Hormone replacement and antiresorptive therapies might be also indicated.
引用
收藏
页码:S101 / S105
页数:5
相关论文
共 42 条
[1]   Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection:: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy [J].
Aukrust, P ;
Haug, CJ ;
Ueland, T ;
Lien, E ;
Müller, F ;
Espevik, T ;
Bollerslev, J ;
Froland, SS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :145-150
[2]   Diagnosis and management of osteoporosis: Guidelines for the utilization of bone densitometry [J].
Baran, DT ;
Faulkner, KG ;
Genant, HK ;
Miller, PD ;
Pacifici, R .
CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (06) :433-440
[3]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[4]   Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [J].
Brinkman, K ;
ter Hofstede, HJM ;
Burger, DM ;
Smeitinkt, JAM ;
Koopmans, PP .
AIDS, 1998, 12 (14) :1735-1744
[5]   Avascular necrosis of bone in patients with human immunodeficiency virus infection: Report of 6 cases and review of the literature [J].
Brown, P ;
Crane, L .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1221-1226
[6]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[7]   Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy [J].
Carr, A ;
Miller, J ;
Eisman, JA ;
Cooper, DA .
AIDS, 2001, 15 (06) :703-709
[8]   Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion [J].
Chariot, P ;
Drogou, I ;
de Lacroix-Szmania, I ;
Eliezer-Vanerot, MC ;
Chazaud, B ;
Lombès, A ;
Schaeffer, A ;
Zafrani, ES .
JOURNAL OF HEPATOLOGY, 1999, 30 (01) :156-160
[9]   HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D [J].
Cozzolino, M ;
Vidal, M ;
Arcidiacono, MV ;
Tebas, P ;
Yarasheski, KE ;
Dusso, AS .
AIDS, 2003, 17 (04) :513-520
[10]   BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES [J].
CUMMINGS, SR ;
BLACK, DM ;
NEVITT, MC ;
BROWNER, W ;
CAULEY, J ;
ENSRUD, K ;
GENANT, HK ;
PALERMO, L ;
SCOTT, J ;
VOGT, TM .
LANCET, 1993, 341 (8837) :72-75